Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

SHOCKING: 2 strong buy biotech growth stocks with over 200 upside potential - What They Never Told You

Growth stocks, particularly those in the biotech sector, can be lucrative long-term investments. The biotech sector often develops cutting-edge treatments (like gene therapy, immuno-oncology, and obesity drugs) that have the potential to redefine the healthcare industry.  Shares of companies in the clinical stage can skyrocket in a short period of time following the success of a clinical trial or FDA approval. 

However, these stocks also carry high risk, as their performance is heavily reliant on innovation, clinical trial success, and regulatory approval. Here are two “Strong Buy”-rated biotech growth stocks with potential upside of more than 200% that Wall Street believes are worth the risk.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.